Manhattan, New York, New York, March 30, 2021 – Bridge Point Capital (BPC) and China Eye Valley (Eye Valley) are pleased to announce that they have entered into a global strategic partnership. This combination of BPC’s proprietary U.S. healthcare deal flow with Eye Valley’s world-class ophthalmology industrial chain and other leading resources i.e., incubators and R&D facilities has breakthrough potential.
“The BPC-Eye Valley partnership is a powerful combination. We bring western healthcare solutions with revolutionary technologies to the Asian market. Eye Valley’s vast network and ample resources in the China market are a perfect fit for our portfolio companies to expand their Asia/China footprints,” said Nadia Tian, Co-founder & Co-CEO of Bridge Point Capital.
China Eye Valley and Its Affiliated Super Eye Hospital
China Eye Valley is an ophthalmology industry park jointly built by Wenzhou National High-Tech Zone and one of the best domestic ophthalmology research institutes – Wenzhou Medical University. The park aims to provide complete industry chain science & technology innovations/solutions to the eye care space. The complex covers an area of 1000+ acres, forming a central incubation park, science & technology innovation park and industrial park concentration zone.
Overall Design of the China Eye Valley
The local Wenzhou government has invested 700+ million RMB in the construction of an area of 80 acres with a building area of 80,000 square meters for its incubation park. An additional area of 1000 acres of science and technology park is planned to meet additional development demand. As of March 2021, the park has attracted over 1.3 billion RMB to be invested into its affiliated/incubated companies.
Highlights of China Eye Valley
Currently, Eye Valley is partnering with the world’s top vision-care companies such as Alcon, Novartis, Allergan, and Menicon; influential domestic companies i.e., Xingqi Eye Medicine, Berry Gene, Aier Eye Hospital, Tsingda Optics to jointly create five world-leading scientific and technological innovation platforms for ophthalmology equipment, visual optics, ophthalmic materials, ophthalmic drugs and smart medical care, bridging the gap between ophthalmology research and the unmet need for vision-related technologies/solutions.
“We’ve seen rapid growth of the demand for more advanced ophthalmology technologies to enter China, and we believe the alliance formed with BPC is tremendously valuable for us to satisfy the needs,” Dr. Qu Jia, Director of China Eye Valley, also the General Dean of Wenzhou Medical University Eye and Optometry Hospital Group, commented. “Having BPC as a strong strategic partner outside of China gives Eye Valley, our local partners and our affiliated companies access to the U.S. capital markets as well as the rest of the world, this is another unique value generated by the formation of the alliance.”
About Bridge Point Capital:
Bridge Point Capital is a private equity firm based in New York, with a focus on U.S-Asia cross-border investments. We specialize in investing in disruptive mid- to late-stage healthcare companies that can benefit from penetrating the vast, yet unexplored Asian healthcare market. We aim to leverage our expertise in both healthcare and capital markets, to establish a lucrative investment platform for our investors.